FDA Approves Purdue’s Extended-Release Opioid With Abuse-Deterrent Properties

The Food and Drug Administration July 23 approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic with abuse-deterrent properties.

The medication, made by Stamford, Conn.-based Purdue Pharma LP, is indicated to treat pain that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection, the agency said. When crushed and snorted, or crushed, dissolved and injected, the naloxone in Targiniq ER blocks the euphoric effects ...